Why the study?
Does combined prophylaxis with ganciclovir and CMV hyperimmune globulin reduce CMV disease and improve survival in high-risk lung transplant recipients?
Population
68 CMV high-risk lung transplant recipients (D+/R-, D+/R+) with a minimum follow-up of 1 year posttransplant
Comparison
Ganciclovir together with CMV hyperimmune… vs Single ganciclovir (GAN) prophylaxis for 3 months
Design
Cohort
Follow-up
Median 16.5 months in control and 23.8 months in study group
Authors
Loading...
May support combined prophylaxis in high-risk lung recipients; leaves open need for randomized confirmation before practice change.
Does combined prophylaxis with ganciclovir and CMV hyperimmune globulin reduce CMV disease and improve survival in high-risk lung transplant recipients?
In high-risk lung transplant recipients, combined prophylaxis with ganciclovir and CMV hyperimmune globulin significantly reduces CMV disease and improves survival compared to ganciclovir alone.
Ruttmann et al. (2006) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: